CD19 and acute lymphoblastic leukemia: The percentages CAR-CD19 positive cells was demonstrated to correlate significantly with cytotoxicity in vitro, performed against a standard CD19+ B-acute lymphoblastic leukemia (ALL) cell line, in the context of our two clinical studies using 60 batches of CIK cells modified with a CAR anti-CD19 (NCT03389035 and NCT05252403 and product validation data for these trials) (Figure 1).